Insight on AstraZeneca’s global R&D Postdoctoral Challenge initiative
AstraZeneca launched a global R&D Postdoctoral Challenge to help accelerate ideas to transform the treatment of some of the world’s most complex... Read More
Astrazeneca has been given the all-clear to buy rare disease drug maker Alexion in a blockbuster £28billion deal.
Astrazeneca has been given the all-clear to buy rare disease drug maker Alexion in a blockbuster £28billion deal. The Competition and Markets... Read More
Covishield received emergency use authorization in India
Covidshield vaccine, developed by AstraZeneca and Oxford University has received for emergency use authorization in India. Drugs Controller General of India (DCGI)... Read More
AstraZeneca, Accent Therapeutics partners to develop transformative therapeutics targeting RMPs to treat cancer
Accent Therapeutics and AstraZeneca forged a collaboration valued at about $1.1 billion to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins... Read More
AstraZeneca and Silence Therapeutics co-development siRNA therapeutics
AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialise small interfering RNA (siRNA) therapeutics for the treatment of cardiovascular (CV),... Read More
AstraZeneca disinvest hypertension medicines to Atnahs Pharma
AstraZeneca divest its global commercial rights of Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide... Read More
Selumetinib NDA Submission for Neurofibromatosis Type 1 (NF1) granted Priority Review
AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration... Read More
AstraZeneca divests Losec (omeprazole) and associated brands rights to Cheplapharm Arzneimittel GmbH
Posted on03 Oct 2019
TagsAcimax, Antra, AstraZeneca, Cheplapharm Arzneimittel GmbH, disinvestment in pharma business, Losec, Mepral, Mopral, Omepral, Zoltum
Comments0
AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands... Read More
AstraZeneca’s Forxiga gets EMA positive opinion for DECLARE-TIMI 58 cardiovascular outcomes data
AstraZeneca announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended a change to the European... Read More
Pharma Disinvestment deal: AstraZeneca to divest Synagis US rights to Sobi
AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused... Read More